Deborah L. Toppmeyer

Deborah Toppmeyer practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Deborah Toppmeyer's NPI, 1114004975, was assigned on November 1, 2006. Deborah Toppmeyer graduated from Albany Medical College of Union University in 1985. Deborah Toppmeyer holds New Jersey license 25MA063107.

Deborah Toppmeyer's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Deborah Toppmeyer also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Deborah Toppmeyer's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. Deborah Toppmeyer is also affiliated with Atlantic Health CentraState Medical Center. The medical group on file is Rutgers-RWJ Scleroderma Program. Dmand AI also links Deborah Toppmeyer to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Deborah Toppmeyer practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Deborah Toppmeyer's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Deborah Toppmeyer is licensed in New Jersey.

CMS data shows 343 Medicare services from Deborah Toppmeyer across 5 procedure codes in 2024, for 177 Medicare patients. Medicare paid $23,346 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 177 Medicare patients who saw Deborah Toppmeyer in 2024. The largest group is 65 to 74, with 92 patients. 75% of them have cancer, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Deborah Toppmeyer's median patient age at 68, with 95% women.

In 2024, Deborah Toppmeyer wrote 413 Medicare Part D claims for 135 patients. 86% of them were for generic drugs. CMS names the drug for 336 of them, across 8 drugs with 11 or more claims each, at $497,655 in total drug cost. In 2023, CMS named 289 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Deborah Toppmeyer for performance year 2024, reported as part of a group. Deborah Toppmeyer accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 48 papers to Deborah Toppmeyer, published from 2012 to 2024. 2018 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Chemotherapy, Adjuvant and Genetic Counseling. Deborah Toppmeyer has published most often in Front Oncol. Deborah Toppmeyer's most frequent co-authors are Bruce G. Haffty, MD, Mridula A. George and Jeffrey L. Berenberg, MD.

Dmand AI links Deborah Toppmeyer to 8 clinical trials, 6 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Carcinoma In Situ and Triple Negative Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 51 general payments to Deborah Toppmeyer from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Novartis Pharmaceuticals Corporation paid the most, $21,632. It also lists 1 research payment totaling $13,125 in 2020.

Deborah Toppmeyer graduated from Albany Medical College of Union University in 1985.